Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1341-1360 of 1,738 trials

TAR-0520 Gel for Folliculitis in Colorectal Cancer Patients

We are testing a new gel to see if it is safe and effective for preventing skin irritation in patients using EGFR inhibitors for colorectal cancer. This study focuses on its use on the face and chest.

Papuloerythematous Drug EruptionEGFR Inhibitor-Induced Folliculitis1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementDermatologyOncology

Pegcetacoplan for Adolescents with Paroxysmal Nocturnal Hemoglobinuria

We are studying the safety and biological activity of pegcetacoplan in patients aged 12-17 with PNH. This trial will help us understand how well the treatment works and its effects on health-related quality of life.

Paroxysmal Nocturnal Hemoglobinuria3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematology

Chronic Urticaria: Testing Remibrutinib

We are exploring whether remibrutinib can help adults with Chronic Urticaria manage their symptoms better than a placebo. The study also looks at the safety of this new treatment and its effects on quality of life.

Chronic Urticaria≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteAllergologyDermatology

Complicated Urinary Tract Infections in Children: Vabomere Study

We are studying the safety and effectiveness of Vabomere for children aged 3 months to under 12 years with complicated urinary tract infections. This research aims to improve treatment options for these young patients.

Complicated Urinary Tract InfectionAcute Pyelonephritis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesUrology

Group B Streptococcus Vaccine: GBS NN/NN2 in Pregnant Women

We are studying the GBS NN/NN2 vaccine to see how long the immune response lasts and how safe it is when given as a booster during a new pregnancy. We also want to understand how well antibodies are passed from mothers to their babies.

Group B Streptococcus Neonatal Sepsis>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboGynecology and ObstetricsInfectious Diseases

Stage IIIA/B NSCLC: New Immunotherapy and Chemotherapy Approach

We are studying a new treatment combining immunotherapy and chemotherapy for patients with resectable stage IIIA/B non-small cell lung cancer. The trial aims to see if this approach improves survival and quality of life compared to standard treatments.

Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Genital Herpes: IM-250 Treatment Study

We are investigating a new medication, IM-250, for people with recurrent genital herpes to see if it can help reduce outbreaks. The study will also look at the safety of this treatment when given weekly.

Genital Herpes≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementDermatologyInfectious Diseases

Post-COVID-19 Condition: Plitidepsin Study

We are investigating whether plitidepsin can improve health outcomes for adults with post-COVID-19 Condition. The study will compare its effects to a placebo on symptoms and overall well-being.

Post-COVID-19 Syndrome3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteCardiologyDiabetologyEndocrinologyGastroenterologyHematologyInfectious DiseasesInternal MedicineNeurologyPsychiatryPulmonologyRheumatology

Acute Bacterial Skin Infections: IV Oritavancin for Kids

We are studying a single-dose intravenous medication for children with acute bacterial skin infections. The trial aims to assess its safety and how well it works compared to existing treatments.

Acute Bacterial Skin and Skin Structure Infection>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyPediatrics

Lyell Syndrome: Mesenchymal Stromal Cells Treatment

We are testing a new treatment using mesenchymal stromal cells for patients with Lyell syndrome. The study aims to see if this treatment can help improve skin healing and overall health.

Lyell Syndrome>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesDermatologyHematology

Glycerol Phenylbutyrate for Pyruvate Dehydrogenase Deficiency

We are studying whether Glycerol Phenylbutyrate can help reduce fatigue and improve quality of life for patients with Pyruvate Dehydrogenase Deficiency. The trial will also assess its safety and effects on neurodevelopmental symptoms.

Pyruvate Dehydrogenase Deficiency1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyGastroenterologyNeurology

Neonatal Hypoxic Ischemic Encephalopathy: Cord Blood Stem Cell Treatment

We are studying the safety and feasibility of using a baby's own cord blood stem cells to treat neonatal hypoxic ischemic encephalopathy. The trial also looks at how this treatment may help prevent long-term neurological problems.

Neonatal Hypoxic-Ischaemic Encephalopathy>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyPediatrics

Kidney Cancer: New Combination Therapies

We are studying new treatment combinations for people with recurrent kidney cancer after anti-PD-(L)1 therapy. The goal is to evaluate their safety and effectiveness in improving patient responses.

Clear Cell Renal Cell Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Luspatercept for Anemia in Lower-Risk MDS Patients

We are studying whether Luspatercept can improve anemia in patients with lower-risk myelodysplastic syndromes who do not require blood transfusions. The trial will also assess its impact on quality of life and safety.

Myelodysplastic Syndromes (MDS)3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematology

Liver Cancer: Tislelizumab Immunotherapy Study

We are testing a new immunotherapy for patients with liver cancer and moderate liver function. The study aims to see if it can improve treatment outcomes and quality of life.

Hepatocellular Carcinoma (HCC)>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHepatologyOncology

Inflammatory Disorders: New Imaging Tracer 18F-AlF-FAPI-74

We are studying a new imaging tracer to see if it can better diagnose inflammatory disorders compared to the standard tracer. This trial includes patients with fever of unknown origin, IgG4-related disease, and axial spondyloarthritis.

Fever of Unknown OriginIgG4-Related DiseaseAxial Spondyloarthritis>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesInternal MedicineOrthopedics and TraumatologyRheumatology

Pancreatic and Bile Duct Cancer: 68Ga-FAPI-46 PET Imaging Study

We are testing a new imaging method to better visualize pancreatic and bile duct cancers. This study aims to see how accurately it detects cancer and monitors treatment response.

Cholangiocarcinoma (Bile Duct Cancer)Pancreatic Carcinoma (Pancreatic Cancer)>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Bleeding Treatment in Thrombocytopenic Patients: FORMAT Study

We are studying whether adding fibrinogen to platelet transfusions helps patients with low platelet counts after chemotherapy stop bleeding. This trial will evaluate the effectiveness and safety of this treatment approach.

Blood Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematology

Rectal Cancer: REGorafenib and Nivolumab Treatment

We are studying a new treatment combining REGorafenib and Nivolumab with short-course radiotherapy for patients with intermediate-risk rectal cancer. The aim is to see if this approach improves treatment response and safety before surgery.

Locally-advanced Rectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Clenbuterol for Spinal and Bulbar Muscular Atrophy (SBMA)

We are studying whether clenbuterol can help patients with SBMA manage their symptoms. We will also look at how well patients tolerate the treatment over time.

Spinal and Bulbar Muscular Atrophy6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesInternal MedicineNeurology